Chai‐Ho, Wanxing
https://orcid.org/0000-0002-0657-836X
Mayo Clinic
University of California, Los Angeles
Citations 2
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily
Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Greenberg, Peter L. , Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Castro, Carlos M. de , Deeg, H. Joachim , Dinner, Shira, Foucar, Charles , Gaensler, Karin, Garcia‐Manero, Guillermo , Keel, Sioḃán , Madanat, Yazan F. , Maness, Lori J., Mangan, James K. , McMahon, Christine M. , Patel, Bhumika J. , Sallman, David A. , Shallis, Rory M. , Shami, Paul J. , Varshavsky‐Yanovsky, Asya, Westervelt, Peter, Hollinger, Elizabeth, Shead, Dorothy A. , Hochstetler, Cindy, Madanat, Yazan , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Head, David, Jonas, Brian A. , McCurdy, Shannon , Reddy, Vishnu , Thota, Swapna , Hollinger, Elizabeth
Journal of the National Comprehensive Cancer Network | February 7, 2022 | Volume: 20 | Issue: 2 | Pages: 106-117
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.